Chen Hangdi, Guo Kai, Bai Zhihao, Lu Liuyi, Liu Bin, Zhang Jiali, Zhong Meiyin, Xu Changfen, Chen Wanghuan, Huang Aiwu, Ding Yuemin
Department of Clinical Medicine, School of Medicine, Hangzhou City University, Hangzhou, China.
Department of Obstetrics and Gynecology, Hangzhou Lin'an District Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hangzhou City University, Hangzhou, China.
Cancer Med. 2025 Apr;14(7):e70847. doi: 10.1002/cam4.70847.
Cervical cancer remains a major global health threat for women, primarily driven by human papillomavirus (HPV) infection. While HPV vaccination serves as the cornerstone of prevention, disparities in vaccine accessibility persist across low-income countries. Secondary prevention through screening faces challenges in public engagement, often leading to late-stage diagnoses. Recent advancements in novel anti-HPV drugs offer expanded opportunities for cervical cancer management.
This review examines emerging anti-HPV therapeutics to provide insights into innovative strategies for cervical cancer prevention and treatment.
We conducted a systematic analysis of published studies investigating anti-HPV agents, focusing on their molecular mechanisms and clinical efficacy in cervical cancer prevention.
RESULTS & CONCLUSIONS: Multiple promising anti-HPV agents have been identified, including 3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin (3HP-β-LG), carrageenan, defensins, and 25-hydroxycholesterol (25HC). These compounds exert antiviral effects through distinct mechanisms: 3HP-β-LG competitively inhibits viral attachment, carrageenan blocks HPV entry via heparan sulfate mimicry, defensins inhibit the dissociation of viral capsid, and 25HC activates cholesterol-mediated antiviral pathways. They have demonstrated strong inhibitory effects on HPV infection, making them novel therapeutic candidates for the prevention and treatment of cervical cancer.
宫颈癌仍然是全球女性面临的主要健康威胁，主要由人乳头瘤病毒（HPV）感染驱动。虽然HPV疫苗接种是预防的基石，但在低收入国家，疫苗可及性方面的差距依然存在。通过筛查进行的二级预防在公众参与方面面临挑战，常常导致晚期诊断。新型抗HPV药物的最新进展为宫颈癌管理提供了更多机会。
本综述研究新兴的抗HPV疗法，以深入了解宫颈癌预防和治疗的创新策略。
我们对已发表的研究抗HPV药物的研究进行了系统分析，重点关注其分子机制和在宫颈癌预防中的临床疗效。
已确定多种有前景的抗HPV药物，包括3-羟基邻苯二甲酸酐修饰的牛β-乳球蛋白（3HP-β-LG）、角叉菜胶、防御素和25-羟基胆固醇（25HC）。这些化合物通过不同机制发挥抗病毒作用：3HP-β-LG竞争性抑制病毒附着，角叉菜胶通过模拟硫酸乙酰肝素阻止HPV进入，防御素抑制病毒衣壳解离，25HC激活胆固醇介导的抗病毒途径。它们已显示出对HPV感染有强大的抑制作用，使其成为预防和治疗宫颈癌的新型治疗候选药物。
